Trial Profile
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 May 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Triamcinolone (Primary)
- Indications Diabetic macular oedema; Diabetic retinopathy
- Focus Registrational; Therapeutic Use
- Acronyms LRT for DME + PRP; Protocol i Study
- 14 Jun 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 14 Jun 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 15 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.